What is OncoPep?
OncoPep, Inc., based in North Andover, Massachusetts, is dedicated to pioneering the development of targeted immunotherapeutics against various forms of cancer. The company's core technology, which it exclusively licenses, centers on a unique combination of proprietary peptides designed to function as a therapeutic cancer vaccine. By stimulating the patient's immune system to target cancer cells, OncoPep's vaccines utilize an optimized blend of disease-specific peptides and immune-boosting adjuvants. This approach positions OncoPep at the forefront of personalized cancer treatment strategies, aiming to enhance patient outcomes through advanced biological therapies.
How much funding has OncoPep raised?
OncoPep has raised a total of $28.4M across 5 funding rounds:
Angel/Seed
$4.5M
Series A
$2.5M
Private Equity
$3.5M
Series B
$6.9M
Series D
$11M
Angel/Seed (2011): $4.5M, investors not publicly disclosed
Series A (2012): $2.5M led by NewSpring Health Capital
Private Equity (2014): $3.5M supported by NewSpring Health Capital
Series B (2014): $6.9M featuring The Leukemia & Lymphoma Society
Series D (2021): $11M backed by CrystalBioScience, KUKJE Pharma, Tera Science, and SX Company
Key Investors in OncoPep
NewSpring Health Capital
NewSpring Health Capital is a venture capital firm that partners with companies in dynamic industries to catalyze new growth, focusing on developing businesses into market leaders through its extensive network.
The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society is a leading nonprofit organization dedicated to fighting blood cancers, investing in groundbreaking research and pioneering innovative approaches to cure cancer.
CrystalBioScience
Undisclosed investor participating in the funding round.
What's next for OncoPep?
The recent major strategic investment in OncoPep, following substantial enterprise-level funding rounds, indicates a strong market validation and confidence in the company's innovative cancer vaccine technology. This capital is expected to accelerate OncoPep's research and development pipeline, potentially enabling further clinical trials, expanding its therapeutic pipeline, and scaling its operational capacity. The company's focus on peptide-based immunotherapeutics aligns with the growing trend in oncology towards precision medicine and immune-based treatments, suggesting a promising trajectory for future growth and market penetration.
See full OncoPep company page
